Biotechnology company Moderna Inc (Nasdaq:MRNA) reported on Wednesday the receipt of the interim authorization of its mRNA vaccine against COVID-19 from Singapore Health Sciences Authority (HSA) under the Pandemic Special Access Route (PSAR).
The Singapore Ministry of Health's authorization of the COVID-19 vaccine is based on the totality of the company's scientific evidence, including a data analysis from the pivotal Phase 3 clinical study announced on 30 November 2020.
Additionally, the company has received authorization for its COVID-19 vaccine from health agencies in the US, Canada, Israel, the EU, the UK and Switzerland. Additional authorizations are currently under review in other countries and by the World Health Organization.
In addition, the Moderna COVID-19 vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein co-developed with the National Institute of Allergy and Infectious Disease's (NIAID) Vaccine Research Center. The first clinical batch was completed on 7 February 2020 and underwent analytical testing. The first participant in the NIAID-led Phase 1 study of the Moderna COVID-19 Vaccine was dosed on 16 March 2020. On 12 May 2020, the US FDA granted the the vaccine Fast Track designation.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary